Perioperative anaesthetic management in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a retrospective analysis in a single tertiary care cancer centre

被引:4
|
作者
Gupta, Raghav [1 ]
Gupta, Nishkarsh [1 ]
Sirohiya, Prashant [1 ]
Pandit, Anuja [1 ]
Ratre, Brajesh Kumar [1 ]
Vig, Saurabh [1 ]
Bhan, Swati [1 ]
Singh, Ram [1 ]
Kumar, Balbir [1 ]
Bhopale, Shweta [1 ]
Mishra, Seema [1 ]
Garg, Rakesh [1 ]
Bharati, Sachidanand Jee [1 ]
Kumar, Vinod [1 ]
Deo, Suryanarayana [2 ]
Bhatnagar, Sushma [1 ]
机构
[1] AIIMS, Dept Oncoanesthesia & Palliat Med, New Delhi 110029, India
[2] All India Inst Med Sci, Dept Surg Oncol, New Delhi, India
关键词
anaesthesia; cancer; cytoreductive surgery; fluid therapy; hyperthermic intraperitoneal chemotherapy; perioperative care; PERITONEAL CARCINOMATOSIS; HOSPITAL STAY; COMPLICATIONS; MORBIDITY; THERAPY; OUTCOMES; TRIAL;
D O I
10.1515/pp-2022-0001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with increased morbidity and mortality. We retrospectively analysed the perioperative anesthetic management in patients undergoing HIPEC surgery. Methods: After ethics approval, we reviewed the records of patients who underwent CRS/HIPEC from 2015 until 2020. We noted the peritoneal carcinomatosis index (PCI), blood loss, anastomoses done, total amount of fluid given, delta temperature and duration of surgery. These were correlated with the need for postoperative ventilation, length of ICU stay, Clavien-Dindo score and 30 day mortality. Results: Of the 180 patients reviewed, the majority were women (85%) with a mean age of 48 years who had ovarian tumors (n=114). The total amount of fluid given was associated with an increased length of ICU stay (p=0.008). Prolonged surgery resulted in increased length of ICU stay (p<0.001), need for postoperative ventilation (p=0.006) and a poor Clavien-Dindo score (p=0.039). A high PCI score correlated with increased ICU stay, 30 day mortality (p<0.001), and the need for postoperative ventilation (0.005). Conclusions: PCI, duration of surgery and blood loss were major predictors of postoperative morbidity. Additionally, the amount of fluid given and delta temperature affected patient outcome and should be individualized to the patient's needs.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 50 条
  • [41] Peritoneal mestastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
    Falla-Zuniga, Luis Felipe
    Sardi, Armando
    King, Mary Caitlin
    Lopez-Ramirez, Felipe
    Barakat, Philipp
    Nieroda, Carol
    Diaz-Montes, Teresa
    Gushchin, Vadim
    PLEURA AND PERITONEUM, 2024, 9 (01) : 15 - 22
  • [42] Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    M. Gaillard
    P. Van Eyken
    G. Verswijvel
    K. Van der Speeten
    Indian Journal of Surgical Oncology, 2023, 14 : 240 - 249
  • [43] Factors affecting dietary progression post cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Stibbard, Allysha
    Brown, Morgan
    Pons, Rachel
    Ward, Jessica
    Page, Naomi
    Stefoska-Needham, Anita
    CLINICAL NUTRITION ESPEN, 2024, 63 : 520 - 529
  • [44] Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
    Nikolaos Vassos
    Thomas Förtsch
    Archil Aladashvili
    Werner Hohenberger
    Roland S. Croner
    World Journal of Surgical Oncology, 14
  • [45] Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Katherin Zambrano-Vera
    Armando Sardi
    Felipe Lopez-Ramirez
    Michelle Sittig
    Carlos Munoz-Zuluaga
    Carol Nieroda
    Vadim Gushchin
    Teresa Diaz-Montes
    Annals of Surgical Oncology, 2021, 28 : 4655 - 4666
  • [46] Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Zambrano-Vera, Katherin
    Sardi, Armando
    Lopez-Ramirez, Felipe
    Sittig, Michelle
    Munoz-Zuluaga, Carlos
    Nieroda, Carol
    Gushchin, Vadim
    Diaz-Montes, Teresa
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) : 4655 - 4666
  • [47] The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum
    Sean P. Dineen
    Jose M. Pimiento
    Annals of Surgical Oncology, 2021, 28 : 4130 - 4137
  • [48] Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from gastric cancer
    Piso, P.
    Glockzin, G.
    Schlitt, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [49] The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
    Guyu Zhang
    Yimin Zhu
    Chongdong Liu
    Guangming Chao
    Ran Cui
    Zhenyu Zhang
    Journal of Ovarian Research, 12
  • [50] The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
    Zhang, Guyu
    Zhu, Yimin
    Liu, Chongdong
    Chao, Guangming
    Cui, Ran
    Zhang, Zhenyu
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)